What Is Estrone (E1)? Normal vs Optimal Range Explained

The lab reference range for estrone spans an enormous 10–200 pg/mL—a twentyfold spread that tells you almost nothing about hormonal health in isolation. Estrone matters most in two contexts: postmenopausal women (where it's the dominant circulating estrogen) and obese individuals of any sex (where excess adipose tissue drives aromatase conversion of adrenal androgens to estrone). The CTD documents over 5,100 compound interactions with estrone-related metabolic pathways, reflecting the extensive pharmacological and environmental influence on this hormone. Optimal estrone between 30 and 150 pg/mL represents adequate estrogenic tone without excess—values below 30 in postmenopausal women correlate with accelerated bone loss, while values persistently above 150 in obese postmenopausal women increase breast and endometrial cancer risk from chronic estrogen stimulation.

The E1-to-E2 ratio is far more clinically informative than either hormone measured alone. In premenopausal women, estradiol (E2) dominates and the E1:E2 ratio is typically below 1:1. After menopause, the ratio reverses—estrone dominates as the ovaries cease estradiol production and adipose tissue becomes the primary estrogen factory. PubMed indexes over 22,000 publications on estrone, with the most clinically relevant finding being the dramatic difference in E1:E2 ratio between oral and transdermal hormone replacement therapy. Oral estrogen undergoes first-pass hepatic metabolism, converting much of the administered estradiol to estrone and creating an unfavorable E1:E2 ratio of approximately 5:1. Transdermal estrogen bypasses the liver, maintaining a more physiologic 1:1 ratio and avoiding the hepatic stimulation of clotting factors and inflammatory markers.

Estrone is a weaker estrogen than estradiol—roughly one-tenth as potent at the estrogen receptor—but its prolonged exposure in postmenopausal women makes cumulative effects significant. Adipose tissue contains aromatase enzyme that converts adrenal androstenedione to estrone, creating a direct proportional relationship between body fat mass and estrone levels. In obese postmenopausal women, this chronic estrone exposure stimulates estrogen-receptor-positive breast tissue and promotes endometrial proliferation, explaining the well-documented association between postmenopausal obesity and hormone-dependent cancers. Weight loss reduces aromatase activity and estrone production—a 10 kg weight loss can reduce circulating estrone by 20–30%, meaningfully lowering hormone-dependent cancer risk without pharmaceutical intervention.